- Home
- WBTN vs RCUS Comparison
WBTN vs RCUS Comparison
Compare WBTN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBTN
- RCUS
- Stock Information
- Founded
- WBTN 2005
- RCUS 2015
- Country
- WBTN United States
- RCUS United States
- Employees
- WBTN N/A
- RCUS N/A
- Industry
- WBTN
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- WBTN
- RCUS Health Care
- Exchange
- WBTN NYSE
- RCUS Nasdaq
- Market Cap
- WBTN 1.1B
- RCUS 906.4M
- IPO Year
- WBTN 2024
- RCUS 2018
- Fundamental
- Price
- WBTN $8.66
- RCUS $8.38
- Analyst Decision
- WBTN Buy
- RCUS Buy
- Analyst Count
- WBTN 6
- RCUS 10
- Target Price
- WBTN $12.92
- RCUS $23.75
- AVG Volume (30 Days)
- WBTN 246.5K
- RCUS 1.1M
- Earning Date
- WBTN 08-07-2025
- RCUS 08-07-2025
- Dividend Yield
- WBTN N/A
- RCUS N/A
- EPS Growth
- WBTN N/A
- RCUS N/A
- EPS
- WBTN N/A
- RCUS N/A
- Revenue
- WBTN $1,347,441,000.00
- RCUS $141,000,000.00
- Revenue This Year
- WBTN $9.01
- RCUS N/A
- Revenue Next Year
- WBTN $14.69
- RCUS $28.73
- P/E Ratio
- WBTN N/A
- RCUS N/A
- Revenue Growth
- WBTN 3.71
- RCUS N/A
- 52 Week Low
- WBTN $6.75
- RCUS $6.50
- 52 Week High
- WBTN $25.66
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- WBTN N/A
- RCUS 42.54
- Support Level
- WBTN N/A
- RCUS $8.36
- Resistance Level
- WBTN N/A
- RCUS $8.87
- Average True Range (ATR)
- WBTN 0.00
- RCUS 0.48
- MACD
- WBTN 0.00
- RCUS -0.12
- Stochastic Oscillator
- WBTN 0.00
- RCUS 9.09
About WBTN WEBTOON ENTERTAINMENT INC
Webtoon Entertainment Inc is a storytelling platform where a vibrant community of creators and users discover, create and share new content. It has pioneered a cultural movement by revolutionizing the storytelling format and democratizing content creation and publication connecting 24 million creators with approximately 170 million monthly active users in over 150 countries around the world.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.